Abstract
The results of the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome [TRA•CER] trial showed that vorapaxar does not significantly improve outcomes in high-risk patients with non-ST-segment elevation acute coronary syndrome and significantly increases the risk of major bleeding, including intracranial hemorrhage.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have